Tacrolimus-Eluting Disk within the Allograft Enables Vascularized Composite Allograft Survival with Site-Specific Immunosuppression without Systemic Toxicity

[1]  J. Plock,et al.  Adipose‐derived stromal cell therapy combined with a short course nonmyeloablative conditioning promotes long‐term graft tolerance in vascularized composite allotransplantation , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  A. Ramirez,et al.  Immunosuppression maintenance in vascularized composite allotransplantation: what is just right? , 2017, Current opinion in organ transplantation.

[3]  R. Rieben,et al.  Intra-graft injection of tacrolimus promotes survival of vascularized composite allotransplantation. , 2017, The Journal of surgical research.

[4]  Byong-Taek Lee,et al.  Preparation and characterization of polycaprolactone–polyethylene glycol methyl ether and polycaprolactone–chitosan electrospun mats potential for vascular tissue engineering , 2017, Journal of biomaterials applications.

[5]  P. Brophy,et al.  Development and validation of a liquid chromatography–mass spectrometric assay for simultaneous determination of tacrolimus and 13‐O‐desmethyl tacrolimus in rat kidney tissue , 2017, Journal of pharmaceutical and biomedical analysis.

[6]  S. Talbot,et al.  Vascularized Composite Allotransplantation at a Crossroad: Adopting Lessons From Technology Innovation to Novel Clinical Applications. , 2017, Transplantation.

[7]  F. Schumacher,et al.  Biocompatibility and characterization of polyglycerol-based thermoresponsive nanogels designed as novel drug-delivery systems and their intracellular localization in keratinocytes , 2017, Nanotoxicology.

[8]  K. Marra,et al.  Single Implantable FK506 Disk Prevents Rejection in Vascularized Composite Allotransplantation , 2017, Plastic and reconstructive surgery.

[9]  J. Duarte,et al.  New strategy of tacrolimus administration in animal model based on tacrolimus-loaded microspheres. , 2016, Transplant immunology.

[10]  S. Nadig.  Transplant Arteriosclerosis. , 2016, Transplantation.

[11]  J. Karp,et al.  A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft , 2014, Science Translational Medicine.

[12]  M. Rela,et al.  Tacrolimus-related adverse effects in liver transplant recipients: Its association with trough concentrations , 2014, Indian Journal of Gastroenterology.

[13]  S. Khalifian,et al.  Immunosuppression and Monitoring of Rejection in Hand Transplantation , 2013, Techniques in hand & upper extremity surgery.

[14]  E. Porrini,et al.  The Higher Diabetogenic Risk of Tacrolimus Depends on Pre‐Existing Insulin Resistance. A Study in Obese and Lean Zucker Rats , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  M. Siemionow,et al.  Effectiveness of Topical Immunosuppressants in Prevention and Treatment of Rejection in Face Allotransplantation , 2013, Transplantation.

[16]  X. Zheng,et al.  Site-Specific Immunosuppression in Vascularized Composite Allotransplantation: Prospects and Potential , 2013, Clinical & developmental immunology.

[17]  J. Hubbell,et al.  Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[18]  S. Ildstad,et al.  Immunosuppressive protocols and immunological challenges related to hand transplantation. , 2011, Hand clinics.

[19]  P. Neuhaus,et al.  Effect of tacrolimus dosing on glucose metabolism in an experimental rat model. , 2010, Annals of transplantation.

[20]  Elias Provencio-Vasquez,et al.  A decade in review , 2010 .

[21]  A. Thomson,et al.  Composite Tissue Vasculopathy and Degeneration Following Multiple Episodes of Acute Rejection in Reconstructive Transplantation , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  A. Thomson,et al.  Daily Topical Tacrolimus Therapy Prevents Skin Rejection in a Rodent Hind Limb Allograft Model , 2009, Plastic and reconstructive surgery.

[23]  W. Sui,et al.  Clinical study of the risk factors of insulin resistance and metabolic syndrome after kidney transplantation. , 2008, Transplant immunology.

[24]  A. Kirk,et al.  The Banff 2007 Working Classification of Skin‐Containing Composite Tissue Allograft Pathology , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  L. C. Spolidorio,et al.  Biochemical evaluation of glycemic levels of long-term tacrolimus therapy in rats. , 2007, Brazilian oral research.

[26]  R. Lechler,et al.  In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. , 2007, Blood.

[27]  M. Sarwal,et al.  A novel, semiquantitative, clinically correlated calcineurin inhibitor toxicity score for renal allograft biopsies. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[28]  W. Seeger,et al.  Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. , 2006, Toxicology and applied pharmacology.

[29]  D. Hammer,et al.  Characterization of biodegradable drug delivery vehicles with the adhesive properties of leukocytes II: effect of degradation on targeting activity. , 2005, Biomaterials.

[30]  M. Lanzettà,et al.  Experimental limb transplantation, part III: induction of tolerance in the rigorous strain combination of Brown Norway donor to Lewis recipient. , 2004, Transplantation proceedings.

[31]  J. Fung.  TACROLIMUS AND TRANSPLANTATION: A DECADE IN REVIEW , 2004, Transplantation.

[32]  R. Wolfe,et al.  Chronic renal failure after transplantation of a nonrenal organ. , 2003, The New England journal of medicine.

[33]  H. Starklint,et al.  Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  M. Brenner,et al.  The spectrum of complications of immunosuppression: is the time right for hand transplantation? , 2002, The Journal of bone and joint surgery. American volume.

[35]  D. Hammer,et al.  Characterization of biodegradable drug delivery vehicles with the adhesive properties of leukocytes. , 2002, Biomaterials.

[36]  P. Boros,et al.  L-Selectin-Dependent Lymphoid Occupancy Is Required to Induce Alloantigen-Specific Tolerance1 , 2002, The Journal of Immunology.

[37]  Fadi G Lakkis,et al.  Immunologic ‘ignorance’ of vascularized organ transplants in the absence of secondary lymphoid tissue , 2000, Nature Medicine.

[38]  S. Sakuma,et al.  FK506 inhibition of histamine release and cytokine production by mast cells and basophils. , 2000, International journal of immunopharmacology.

[39]  G. Tydén,et al.  Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. , 1999, British journal of clinical pharmacology.

[40]  R A Nash,et al.  Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. , 1998, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[41]  A. Matas,et al.  An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. , 1996, Transplantation.

[42]  A. Thomson,et al.  Mode of Action of Tacrolimus (FK506): Molecular and Cellular Mechanisms , 1995, Therapeutic drug monitoring.